BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

The EGFR and TGFβ signaling pathways are important mediators of tumorigenesis, and cross-talk between them contributes to cancer progression and drug resistance. Therapies capable of simultaneously targeting EGFR and TGFβ could help improve patient outcomes across various cancer types. Here, we deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Boreddy, Srinivas Reddy, Nair, Reshmi, Pandey, Prashant Kumar, Kuriakose, Anshu, Marigowda, Shivakumar Bhadravathi, Dey, Chaitali, Banerjee, Arindam, Kulkarni, Hanumant, Sagar, Milind, Krishn, Shiv Ram, Rao, Shruthi, AR, Madhukara, Tiwari, Vinita, Alke, Bhavna, MV, Prashantha Kumar, Shri, Meena, Dhamne, Chaitrali, Patel, Sonal, Sharma, Pinky, Periyasamy, Sankar, Bhatnagar, Jaya, Kuriakose, Moni Abraham, Reddy, Ram Bhupal, Suresh, Amritha, Sreenivas, Suma, Govindappa, Nagaraja, Moole, Praveen Reddy, Bughani, Usha, Tan, Seng-Lai, Nair, Pradip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Therapeutic Development and Chemical Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236157/
https://www.ncbi.nlm.nih.gov/pubmed/37074042
http://dx.doi.org/10.1158/0008-5472.CAN-21-4425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236157/
https://www.ncbi.nlm.nih.gov/pubmed/37074042
http://dx.doi.org/10.1158/0008-5472.CAN-21-4425

Ejemplares similares